Match tier
Institution-verified
Presence
Current · Arkansas
Last published
2026
Sources
Institutional record
Refreshed
2026-08-08
O
Omar Atiq
Sourced from institutional research profiles (UAMS TRI or ARA).
PhD
Also affiliated: NXP (Netherlands) (2024); Dutch Polymer Institute (2022–2023); University of Bologna (2022–2026)
Faculty Researcher
4 h-index
10 pubs
86 cited
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Omar Atiq's research centers on the molecular and material science aspects of polymers and membranes, with a recent expansion into clinical oncology. His work includes modeling and experimentally studying gas solubility and transport properties in semi-crystalline polymers such as high-performance polyamides and polyoxymethylene copolymer. These investigations aim to understand material behavior at a molecular level, considering factors like tie-chain fractions and surface effects, and exploring potential applications in barrier technologies. Additionally, Atiq has been involved in clinical research, specifically a randomized double-blind placebo-controlled phase I/II clinical trial evaluating a therapeutic vaccine for reducing head and neck squamous cell carcinoma recurrence. His publications in these areas demonstrate a capacity for both theoretical modeling and experimental investigation across different scientific disciplines.
Metrics
- h-index: 4
- Publications: 10
- Citations: 86
Selected Publications
-
A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence (2026)
Grants & Funding
As listed on this researcher's institutional profile.
- Understanding and Enhancing T-Cell Responses to High Risk Human Papillomaviruses-Renewal NIH
- A Phase 3 Study of Fixed Dose Combinations of Fianlimab and Cemiplimab versus Relatlimab and Nivolumab in Participants with Unresectable or Metastatic Melanoma Regeneron Pharmaceuticals
- A Phase 3 Study of Fixed Dose Combinations of Fianlimab and Cemiplimab versus Relatlimab and Nivolumab in Participants with Unresectable or Metastatic Melanoma ICON Clinical Research via Regeneron Pharmaceuticals
Collaboration Network
Top Collaborators
Emily Ward Bivens
University of Arkansas for Medical Sciences
1 shared publication
In database
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
Teresa Evans
University of Arkansas for Medical Sciences
1 shared publication
In database
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
Ginger Brown
Winthrop Rockefeller Foundation
1 shared publication
In database
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
Jasmine Crane
University of Arkansas for Medical Sciences
1 shared publication
In database
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
Nadia Darwish
University of Arkansas for Medical Sciences
1 shared publication
In database
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
Jennifer L. Faulkner
Winthrop Rockefeller Foundation
1 shared publication
In database
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
Rangaswamy Govindarajan
University of Arkansas for Medical Sciences
1 shared publication
In database
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
Aaron Johnson
Winthrop Rockefeller Foundation
1 shared publication
In database
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
Alongkorn Kurilung
University of Arkansas for Medical Sciences
1 shared publication
In database
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
Oxana P. Lazarenko
University of Arkansas for Medical Sciences
1 shared publication
In database
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
Yong-Chen William Lu
University of Arkansas for Medical Sciences
1 shared publication
In database
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
Keanna Marsh
University of Arkansas for Medical Sciences
1 shared publication
In database
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
M Moreno
University of Arkansas for Medical Sciences
1 shared publication
In database
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
Intawat Nookaew
University of Arkansas for Medical Sciences
1 shared publication
In database
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
Michael Robeson
University of Arkansas for Medical Sciences
1 shared publication
In database
- A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence
Similar Researchers
Based on overlapping research topics
Nazanin Abbasi
University of Arkansas at Fayetteville
Materials Science Research
Membrane Separation Technologies
Molecular Biology Techniques and Applications
Hazim Aljewari
University of Arkansas at Fayetteville
Materials Science Research
Membrane Separation Technologies
Cancer Treatment and Pharmacology
Brianna Bair
University of Arkansas at Fayetteville
Materials Science Research
Membrane Separation Technologies
Zhexi Zhu
University of Arkansas at Fayetteville
Materials Science Research
Membrane Separation Technologies
Sandrina Svetlana DePaz
University of Arkansas at Fayetteville
Materials Science Research
Membrane Separation Technologies
Lucia Milans del Bosch
University of Arkansas at Fayetteville
Materials Science Research
Membrane Separation Technologies